CED Regulatory Digest: Latest Cannabinoid Labeling Guidance Updates
This CED Regulatory Digest covers the latest cannabinoid labeling guidance updates from the FDA docket. It highlights key compliance posture changes and agency comment reviews. Stay informed on regulatory developments affecting cannabinoid products.
Policy Watch: 10 Regulatory Updates — March 19, 2026
This update covers DEA synthetic opioid scheduling and regulatory changes relevant to cannabis clinicians. The focus is on new Schedule I placements and their clinical implications. These regulatory updates inform patient care and research considerations.
Policy Watch: 25 Regulatory Updates — March 12, 2026
The March 12, 2026 update covers DEA scheduling synthetic drugs and related regulatory affairs. This includes synthetic opioids and marijuana rescheduling proposals. Clinicians should note implications for controlled substances management.
Policy Watch: 26 Regulatory Updates — March 08, 2026
The marijuana rescheduling proposal is a key focus in the March 2026 regulatory updates. This change could impact cannabis clinical practice and research access. Marijuana rescheduling remains central to evolving federal cannabis policy.
America Doesn’t Have a Marijuana Problem, It Has a Cannabis Education Gap
The cannabis education gap is a critical issue slowing clinical program development and physician training. Without proper cannabis education, patients lack access to safe, guided care. Addressing this gap is essential for advancing clinical cannabis use.